Durata Therapeutics (FRA:DTA) Net Margin % : -199.30% (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is Durata Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Durata Therapeutics's Net Income for the three months ended in Sep. 2014 was €-15.59 Mil. Durata Therapeutics's Revenue for the three months ended in Sep. 2014 was €7.82 Mil. Therefore, Durata Therapeutics's net margin for the quarter that ended in Sep. 2014 was -199.30%.

The historical rank and industry rank for Durata Therapeutics's Net Margin % or its related term are showing as below:

FRA:DTA' s Net Margin % Range Over the Past 10 Years
Min: -730.11 Med: 0 Max: 0
Current: -730.11

FRA:DTA's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -157.22 vs FRA:DTA: -730.11

Durata Therapeutics Net Margin % Historical Data

The historical data trend for Durata Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics Net Margin % Chart

Durata Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Net Margin %

Durata Therapeutics Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Net Margin %	Get a 7-Day Free Trial							-	-	-	-	-199.30

Competitive Comparison of Durata Therapeutics's Net Margin %

For the Biotechnology subindustry, Durata Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Durata Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's Net Margin % falls into.

Durata Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Durata Therapeutics's Net Margin for the fiscal year that ended in Dec. 2013 is calculated as

Net Margin	=	Net Income (A: Dec. 2013 )	/	Revenue (A: Dec. 2013 )
	=	-45.363	/	0
	=	%

Durata Therapeutics's Net Margin for the quarter that ended in Sep. 2014 is calculated as

Net Margin	=	Net Income (Q: Sep. 2014 )	/	Revenue (Q: Sep. 2014 )
	=	-15.591	/	7.823
	=	-199.30 %

Durata Therapeutics (FRA:DTA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Durata Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Durata Therapeutics (FRA:DTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.duratatherapeutics.com

Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines